Supernus Pharmaceuticals (SUPN) Consolidated Net Income (2011 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Consolidated Net Income of -$58.4 million for Q2 2026, down 359.44% year-over-year from $22.5 million in Q2 2025, and down 1311.97% on a QoQ basis from -$4.1 million in Q4 2025.
Supernus Pharmaceuticals (SUPN) Consolidated Net Income (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Consolidated Net Income for 16 years, with the latest figure at -$58.4 million in Q2 2026.
- Consolidated Net Income for Q2 2026 came in at -$58.4 million, down 359.44% year-over-year; the trailing twelve-month figure through Jun 2026 was -$107.6 million (down 266.75% YoY), and the FY2025 annual result was -$38.6 million, down 152.19% from the prior year.
- Consolidated Net Income fell to -$58.4 million in Q2 2026, from -$4.1 million in the prior quarter.
- Over five years, Consolidated Net Income peaked at $38.5 million in Q3 2024 and troughed at -$58.4 million in Q2 2026.
- A 5-year average of $2.3 million and a median of $1.8 million in 2022 frame the typical range for Consolidated Net Income.
- The widest annual swing landed in 2024, when Consolidated Net Income jumped 2506.53%; it then slumped 9641.13% in 2025.
- A 5-year view of Consolidated Net Income shows it stood at $25.5 million in 2022, then tumbled by 95.39% to $1.2 million in 2023, then jumped by 1208.68% to $15.4 million in 2024, then slumped by 126.88% to -$4.1 million in 2025, then sank by 1311.97% to -$58.4 million in 2026.
- Per Business Quant data, the three most recent Consolidated Net Income figures were -$58.4 million in Q2 2026, -$4.1 million in Q4 2025, and -$45.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Supernus Pharmaceuticals | 2.74 Bn | 2.37 Bn | 185.39 Mn | -58.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -58.37 Mn |
| Dec 31, 2025 | -4.11 Mn |
| Sep 30, 2025 | -45.12 Mn |
| Jun 30, 2025 | 22.50 Mn |
| Mar 31, 2025 | -11.83 Mn |
| Dec 31, 2024 | 15.33 Mn |
| Sep 30, 2024 | 38.54 Mn |
| Jun 30, 2024 | 19.90 Mn |
| Mar 31, 2024 | 143,000.00 |
| Dec 31, 2023 | 1.18 Mn |
| Sep 30, 2023 | -15.98 Mn |
| Jun 30, 2023 | -827,000.00 |
| Mar 31, 2023 | 16.95 Mn |
| Dec 31, 2022 | 25.51 Mn |
| Sep 30, 2022 | 1.75 Mn |
| Jun 30, 2022 | 7.87 Mn |
| Mar 31, 2022 | 25.62 Mn |
| Dec 31, 2021 | 2.44 Mn |
| Sep 30, 2021 | 21.56 Mn |
| Jun 30, 2021 | 23.73 Mn |